{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:58:54Z","timestamp":1793134734359,"version":"4.5.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Presatovir is an oral respiratory syncytial virus (RSV) fusion inhibitor targeting RSV F protein. In a double-blind, placebo-controlled study in healthy adults experimentally infected with RSV (Memphis-37b), presatovir significantly reduced viral load and clinical disease severity in a dose-dependent manner.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Viral RNA from nasal wash samples was amplified and the F gene sequenced to monitor presatovir resistance. Effects of identified amino acid substitutions on in vitro susceptibility to presatovir, viral fitness, and clinical outcome were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-eight treatment-emergent F substitutions were identified. Of these, 26 were tested in vitro; 2 were not due to lack of recombinant virus recovery. Ten substitutions did not affect presatovir susceptibility, and 16 substitutions reduced RSV susceptibility to presatovir (2.9- to 410-fold). No substitutions altered RSV susceptibility to palivizumab or ribavirin. Frequency of phenotypically resistant substitutions was higher with regimens containing lower presatovir dose and shorter treatment duration. Participants with phenotypic presatovir resistance had significantly higher nasal viral load area under the curve relative to those without, but substitutions did not significantly affect peak viral load or clinical manifestations of RSV disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Emergence of presatovir-resistant RSV occurred during therapy but did not significantly affect clinical efficacy in participants with experimental RSV infection.<\/jats:p><\/jats:sec>","DOI":"10.1093\/infdis\/jiaa028","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T04:28:56Z","timestamp":1579667336000},"page":"1468-1477","source":"Crossref","is-referenced-by-count":25,"title":["Drug Resistance Assessment Following Administration of Respiratory Syncytial Virus (RSV) Fusion Inhibitor Presatovir to Participants Experimentally Infected With RSV"],"prefix":"10.1093","volume":"222","author":[{"given":"Kirsten","family":"Stray","sequence":"first","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Perron","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle P","family":"Porter","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Anderson","sequence":"additional","affiliation":[{"name":"Pivot Bio, Berkeley, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra A","family":"Lewis","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Perry","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Miller","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Cihlar","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"DeVincenzo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Tennessee College of Medicine, Memphis, Tennessee, USA"},{"name":"Department of Microbiology, Immunology and Biochemistry, University of Tennessee College of Medicine, Memphis, Tennessee, USA"},{"name":"Children\u2019s Foundation Research Institute, Le Bonheur Children\u2019s Hospital, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason W","family":"Chien","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jordan","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"2020110419122499600_CIT0001","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/jama.282.15.1440","article-title":"Bronchiolitis-associated hospitalizations among US children, 1980\u20131996","volume":"282","author":"Shay","year":"1999","journal-title":"JAMA"},{"key":"2020110419122499600_CIT0002","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"key":"2020110419122499600_CIT0003","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40121-016-0137-7","article-title":"Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with chronic lung disease","volume":"5","author":"Paes","year":"2016","journal-title":"Infect Dis Ther"},{"key":"2020110419122499600_CIT0004","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1542\/peds.2013-0303","article-title":"Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age","volume":"132","author":"Hall","year":"2013","journal-title":"Pediatrics"},{"key":"2020110419122499600_CIT0005","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1067\/S0022-3476(03)00510-9","article-title":"Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000","volume":"143","author":"Leader","year":"2003","journal-title":"J Pediatr"},{"key":"2020110419122499600_CIT0006","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1055\/s-0036-1584147","article-title":"SENTINEL1: an observational study of respiratory syncytial virus hospitalizations among U.S. infants born at 29 to 35 weeks\u2019 gestational age not receiving immunoprophylaxis","volume":"34","author":"Anderson","year":"2017","journal-title":"Am J Perinatol"},{"key":"2020110419122499600_CIT0007","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40121-016-0130-1","article-title":"Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among preterm infants without chronic lung disease or congenital heart disease","volume":"5","author":"Figueras-Aloy","year":"2016","journal-title":"Infect Dis Ther"},{"key":"2020110419122499600_CIT0008","doi-asserted-by":"crossref","first-page":"e1453","DOI":"10.1542\/peds.2010-0507","article-title":"Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis","volume":"126","author":"Garc\u00eda","year":"2010","journal-title":"Pediatrics"},{"key":"2020110419122499600_CIT0009","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ppul.23570","article-title":"Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis","volume":"52","author":"Stein","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"2020110419122499600_CIT0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/INF.0b013e31822e68e6","article-title":"Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997\u20132006","volume":"31","author":"Stockman","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"2020110419122499600_CIT0011","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1097\/TP.0b013e3181a4857d","article-title":"Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study","volume":"87","author":"Gottlieb","year":"2009","journal-title":"Transplantation"},{"key":"2020110419122499600_CIT0012","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1164\/rccm.200310-1359OC","article-title":"Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death","volume":"170","author":"Khalifah","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2020110419122499600_CIT0013","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/jac\/dkt111","article-title":"Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections","volume":"68","author":"Shah","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020110419122499600_CIT0014","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/infdis\/jix390","article-title":"Supplemental oxygen-free days in hematopoietic cell transplant recipients with respiratory syncytial virus","volume":"216","author":"Waghmare","year":"2017","journal-title":"J Infect Dis"},{"key":"2020110419122499600_CIT0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/eri.10.140","article-title":"Respiratory syncytial virus disease: update on treatment and prevention","volume":"9","author":"Krilov","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2020110419122499600_CIT0016","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/infdis\/jiu828","article-title":"Challenges and opportunities in developing respiratory syncytial virus therapeutics","volume":"211","author":"Sim\u00f5es","year":"2015","journal-title":"J Infect Dis"},{"key":"2020110419122499600_CIT0017","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1128\/JVI.75.15.6825-6834.2001","article-title":"Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and\/or attachment glycoprotein gene","volume":"75","author":"Techaarpornkul","year":"2001","journal-title":"J Virol"},{"key":"2020110419122499600_CIT0018","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1006\/viro.2001.1340","article-title":"Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus","volume":"294","author":"Techaarpornkul","year":"2002","journal-title":"Virology"},{"key":"2020110419122499600_CIT0019","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1021\/jm5017768","article-title":"Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study","volume":"58","author":"Mackman","year":"2015","journal-title":"J Med Chem"},{"key":"2020110419122499600_CIT0020","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1128\/AAC.01497-15","article-title":"GS-5806 inhibits a broad range of respiratory syncytial virus clinical isolates by blocking the virus-cell fusion process","volume":"60","author":"Perron","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110419122499600_CIT0021","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1128\/AAC.49.6.2460-2466.2005","article-title":"Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms","volume":"49","author":"Douglas","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110419122499600_CIT0022","doi-asserted-by":"crossref","first-page":"E3441","DOI":"10.1073\/pnas.1405198111","article-title":"Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors","volume":"111","author":"Yan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020110419122499600_CIT0023","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nchembio.1982","article-title":"Molecular mechanism of respiratory syncytial virus fusion inhibitors","volume":"12","author":"Battles","year":"2016","journal-title":"Nat Chem Biol"},{"key":"2020110419122499600_CIT0024","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1401184","article-title":"Oral GS-5806 activity in a respiratory syncytial virus challenge study","volume":"371","author":"DeVincenzo","year":"2014","journal-title":"N Engl J Med"},{"key":"2020110419122499600_CIT0025","doi-asserted-by":"crossref","first-page":"e113100","DOI":"10.1371\/journal.pone.0113100","article-title":"Respiratory syncytial virus human experimental infection model: provenance, production, and sequence of low-passaged memphis-37 challenge virus","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS One"},{"key":"2020110419122499600_CIT0026","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1073\/pnas.92.25.11563","article-title":"Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5\u2019 proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development","volume":"92","author":"Collins","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020110419122499600_CIT0027","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1128\/AAC.48.2.413-422.2004","article-title":"Orally active fusion inhibitor of respiratory syncytial virus","volume":"48","author":"Cianci","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110419122499600_CIT0028","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0042-6822(03)00115-6","article-title":"Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay","volume":"311","author":"Morton","year":"2003","journal-title":"Virology"},{"key":"2020110419122499600_CIT0029","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1073\/pnas.0910108106","article-title":"Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein","volume":"107","author":"Roymans","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020110419122499600_CIT0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1086\/318537","article-title":"Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir","volume":"183","author":"Gubareva","year":"2001","journal-title":"J Infect Dis"},{"key":"2020110419122499600_CIT0031","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(04)16934-1","article-title":"Resistant influenza A viruses in children treated with oseltamivir: descriptive study","volume":"364","author":"Kiso","year":"2004","journal-title":"Lancet"},{"key":"2020110419122499600_CIT0032","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-200102000-00002","article-title":"Oral oseltamivir treatment of influenza in children","volume":"20","author":"Whitley","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"2020110419122499600_CIT0033","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1098\/rstb.2001.1002","article-title":"Treatment of influenza with neuraminidase inhibitors: virological implications","volume":"356","author":"Roberts","year":"2001","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"2020110419122499600_CIT0034","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.antiviral.2013.03.014","article-title":"Influenza virus resistance to neuraminidase inhibitors","volume":"98","author":"Samson","year":"2013","journal-title":"Antiviral Res"},{"key":"2020110419122499600_CIT0035","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/135965350701200S04.1","article-title":"Influenza virus susceptibility and resistance to oseltamivir","volume":"12","author":"Aoki","year":"2007","journal-title":"Antivir Ther"},{"key":"2020110419122499600_CIT0036","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1128\/AAC.01339-05","article-title":"Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use","volume":"50","author":"Monto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110419122499600_CIT0037","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dki018","article-title":"Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic","volume":"55","author":"Ward","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2020110419122499600_CIT0038","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/irv.12534","article-title":"Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the influenza resistance information study","volume":"12","author":"Lina","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"2020110419122499600_CIT0039","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/INF.0b013e3181de9d24","article-title":"Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation","volume":"29","author":"Saito","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"2020110419122499600_CIT0040","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/508777","article-title":"Characterization of multidrug-resistant influenza A\/H3N2 viruses shed during 1 year by an immunocompromised child","volume":"43","author":"Baz","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020110419122499600_CIT0041","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1086\/651605","article-title":"Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts","volume":"50","author":"Memoli","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020110419122499600_CIT0042","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.antiviral.2018.07.020","article-title":"Comparison of antiviral resistance across acute and chronic viral infections","volume":"158","author":"Mason","year":"2018","journal-title":"Antiviral Res"},{"key":"2020110419122499600_CIT0043","doi-asserted-by":"crossref","first-page":"7286","DOI":"10.1128\/JVI.00038-14","article-title":"Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure","volume":"88","author":"Grad","year":"2014","journal-title":"J Virol"},{"key":"2020110419122499600_CIT0044","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.virol.2017.07.017","article-title":"Deep sequencing of RSV from an adult challenge study and from naturally infected infants reveals heterogeneous diversification dynamics","volume":"510","author":"Lau","year":"2017","journal-title":"Virology"},{"key":"2020110419122499600_CIT0045","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz1166","article-title":"A phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients [manuscript published online ahead of print 3 December 2019]","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020110419122499600_CIT0046","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/j.healun.2018.01.375","article-title":"A phase 2b, randomized controlled trial of presatovir, an oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in lung transplant (LT) recipients","volume":"37","author":"Gottlieb","year":"2018","journal-title":"J Heart Lung Transplant"},{"key":"2020110419122499600_CIT0047","first-page":"A4457","article-title":"A phase 2b, randomized, double-blind, placebo-controlled trial of presatovir (GS-5806), a novel oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in hospitalized adults","volume":"197","author":"Hanfelt-Goade","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2020110419122499600_CIT0048","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz1167","article-title":"A phase 2b, randomized, double-blind, placebo-controlled multicenter study evaluating antiviral effects, pharmacokinetics, safety, and tolerability of presatovir in hematopoietic cell transplant recipients with respiratory syncytial virus (RSV) infection of the lower respiratory tract [manuscript published online ahead of print 3 December 2019]","author":"Marty","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa028\/32502215\/jiaa028.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/9\/1468\/33828399\/jiaa028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/222\/9\/1468\/33828399\/jiaa028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T07:35:10Z","timestamp":1665560110000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/222\/9\/1468\/5714799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,2,11]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa028","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11,1]]},"published":{"date-parts":[[2020,2,11]]}}}